Celularity Inc Ordinary Shares - Class A CELU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CELU is a good fit for your portfolio.
News
-
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
-
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
-
Celularity Inc. to Host Investor and Analyst Research & Development Day
-
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
-
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
-
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
-
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
-
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
Trading Information
- Previous Close Price
- $2.98
- Day Range
- $2.98–3.31
- 52-Week Range
- $1.59–8.90
- Bid/Ask
- $3.11 / $3.65
- Market Cap
- $67.74 Mil
- Volume/Avg
- 18,493 / 66,747
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 225
- Website
- https://www.celularity.com
Comparables
Valuation
Metric
|
CELU
|
VOR
|
PRLD
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.91 | 0.75 | 1.00 |
Price/Sales | 3.56 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CELU
VOR
PRLD
Financial Strength
Metric
|
CELU
|
VOR
|
PRLD
|
---|---|---|---|
Quick Ratio | 0.08 | 8.13 | 11.44 |
Current Ratio | 0.19 | 8.46 | 11.64 |
Interest Coverage | −76.30 | — | — |
Quick Ratio
CELU
VOR
PRLD
Profitability
Metric
|
CELU
|
VOR
|
PRLD
|
---|---|---|---|
Return on Assets (Normalized) | −32.92% | −48.29% | −39.87% |
Return on Equity (Normalized) | −79.11% | −61.06% | −44.79% |
Return on Invested Capital (Normalized) | −52.72% | −54.20% | −43.35% |
Return on Assets
CELU
VOR
PRLD
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rdmfjqkgb | Qnwk | $590.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rbpfdymp | Xrdzvjb | $113.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dkdmylbk | Xwhqm | $108.0 Bil | |
MRNA
| Moderna Inc | Nszsxbpk | Wsgrw | $54.6 Bil | |
BNTX
| BioNTech SE ADR | Xprnrykr | Nhy | $24.2 Bil | |
ARGX
| argenx SE ADR | Xhklmxth | Flsr | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wvyzztpfz | Kkkqzf | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ndsyznwlf | Vkqtks | $14.3 Bil | |
INCY
| Incyte Corp | Qbygyxn | Hyfxhy | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Plrqwcdhq | Gwprql | $12.4 Bil |